Company profile
Standard BioTools Inc.
NASDAQ: LAB · Healthcare · Medical - Equipment & Services
#365 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
61CFH 56DQ 77GM 37SS 72
v0.1 · 65/100 weight · provisional
↑ disclosure history, workforce scale · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$86.3M
Rev growth YoY (TTM)
-35.8%
Net income (FY)
-$74.9M
Employees
387
as of 2026-08-12
Market cap
$308.3M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$85.3M$85.3M2025
Net income-$74.9M-$74.9M2025
Operating income-$110.2M-$110.2M2025
Total assets$567.8M$567.8M2025
Liabilities$143.5M$143.5M2025
Equity$424.3M$424.3M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product42%
Consumables25%
Instruments17%
Service and Other Revenue16%
By geography
EMEA42%
Americas36%
Asia Pacific22%
The read
What is Standard BioTools Inc.’s revenue?
Standard BioTools Inc. booked $85.3M in FY2025 revenue, contracting 51% year over year — slower than 82% of Healthcare companies we track, at a -87.8% net margin.
Peers · Healthcare
Fluent Corp.45DHarvard Bioscience, Inc.58C4Front Ventures Corp.——Delcath Systems, Inc.72B4D Molecular Therapeutics, Inc.58CARS Pharmaceuticals, Inc.41DNeighbors
Suffolk →Key facts
CEOMichael Egholm
SectorHealthcare
IndustryMedical - Equipment & Services
HeadquartersBoston, MA
ExchangeNASDAQ: LAB
Employees387
IPO date2011-02-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.